A report in the December 1999 issue of CDU on the annual scientific sessions of the American Heart Association included some incorrect information on the progress of trials being conducted on TherOx's (Irvine, California) SOS Supply System for addressing the problem of reperfusion microvascular ischemia. The story indicated that Richard Spears, MD, of Wayne State University (Detroit, Michigan) had studied myocardial infarction (MI) patients, but he had in fact directed what TherOx President Paul Zalesky, PhD, noted were "several series of animal studies." Zalesky also noted that, while the story said no improvement in ventricular function was observed in Spears' studies, "infarct size was measured and quantitated, and corresponding ventricular function performance improvement was documented." He also noted that TherOx completed a 28-patient Phase I investigational device exemption study in acute MI patients in 1999, demonstrating both safety (no adverse events or complications) and improved cardiac function trend. Zalesky said infarct size was not measured in that study. The story incorrectly reported TherOx's location as Costa Mesa, California.